Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study
Xiaoning Wu(Hebei Medical University), Hong You(Capital Medical University), Yameng Sun(Shanghai Jiao Tong University), Jilin Cheng(Beijing Ditan Hospital), Mingyi Xu(Shanghai Jiao Tong University), Yongpeng Chen(Nanfang Hospital), Qing Xie(Ruijin Hospital), Huiguo Ding(Capital Medical University), Jialing Zhou(Capital Medical University), Wen Xie(Capital Medical University), Mingxiang Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Xuqing Zhang(Rubius Therapeutics (United States)), Wei Jiang(Sun Yat-sen University), Jun Cheng(Capital Medical University), Shuyan Chen(Capital Medical University), Lang Bai(West China Hospital of Sichuan University), Hongxin Piao(Yanbian University Hospital), Hong Ma(Beijing Friendship Hospital), Yiwen Shi(Capital Medical University), Shi-Bin Xie(Third Affiliated Hospital of Guangzhou Medical University), Bingqiong Wang(Capital Medical University), Xiaojuan Ou(Capital Medical University), Jia Shang(Henan Provincial People's Hospital), Anlin Ma(China-Japan Friendship Hospital), Jidong Jia
Cited by 44
Related Papers
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis
|Journal of Hepatology|2020|346
Adding pegylated interferon to entecavir for hepatitis B e antigen–positive chronic hepatitis B: A multicenter randomized trial (ARES study)
|Hepatology|2014|165
New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment
|Hepatology|2016|156